Drug-associated nutritional problems in older persons

Reviews in Clinical Gerontology

Volumn 13, Issue 3, 2004, Pages 183-193

  Chau, Long ^a   Ratnaike, Ranjit N ^b  

^a St Joseph's Hospital   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CYTOTOXIC AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FLUOXETINE; GALANTAMINE; GOLD; HYDROXYCHLOROQUINE SULFATE; ISOCARBOXAZID; NEFAZODONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PSYCHOTROPIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; UNINDEXED DRUG;

AGED; ANOREXIA; ANOSMIA; BACTERIAL INFECTION; CHRONIC DIARRHEA; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG INDUCED DISEASE; DRUG USE; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FOLIC ACID DEFICIENCY; GASTRITIS; GINGIVA HYPERPLASIA; HIGH RISK POPULATION; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; IRON DEFICIENCY; LICHEN PLANUS; MALABSORPTION; MALNUTRITION; NAUSEA; NUTRITIONAL STATUS; OSMOTIC DIARRHEA; OSTEOPOROSIS; PEPTIC ULCER; POLYPHARMACY; PRESCRIPTION; PREVALENCE; PYRIDOXINE DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMATITIS; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 3242689775     PISSN: 09592598     EISSN: None     Source Type: Journal    
DOI: 10.1017/S095925980300100X     Document Type: Review

References (100)

1. McWhirter JP, Pennington CR. Incidence and recognition of malnutrition in hospital. BMJ 1994; 308: 945-48.
2. Larsson J, Unosson M, Ek AC et al. Effect of dietary supplement on nutritional status and clinical outcome in 501 geriatric patients - a randomised study. Clin Nutr 1990; 9: 179-84.
3. Bienia R, Ratcliff S, Barbour GL, Kummer M. Malnutrition in the hospitalized geriatric patient. J Am Geriatr Soc 1982; 30: 433-36.
4. Silver AJ, Morley JE, Strome LS, Jones D, Vickers L. Nutritional status in an academic nursing home. J Am Geriatr Soc 1988; 36: 487-91.
5. Lovat LB. Age-related changes in gut physiology and nutritional status. Gut 1996; 38: 306-09.
6. Vellas B, Guigoz Y, Garry PJ et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999; 15: 116-22.
7. Zachariah KC, Vu MT. World Population Projections 1987-1988: Short and Long-Term Estimates. Baltimore: Johns Hopkins University, 1988.
8. Garibaldi RA, Nurse BA. Infections in the elderly [Review]. Am J Med 1986; 81: 53-58.
9. Lamy PP, Michocki RJ. Medication management [Review]. Clin Geriatr Med 1988; 4: 623-38.
10. Chen LH, Liu S, Newell ME, Barnes K. Survey of drug use by the elderly and possible impact of drugs on nutritional status. Drug Nutr Interact 1985; 3: 73-86.
11. Livingston J, Reeves JD. Undocumented potential drug interactions found in medical records of elderly patients in a long term care facility. J Am Diet Assoc 1993; 93: 1168-1170.
12. Stoller EP, Forster LE, Portugal S. Self-care responses to symptoms by older people. A health diary study of illness behaviour. Med Care 1993; 31: 24-42.
13. Soni N, Bajaj B. Toxic effects of cisplatin on olfaction. Pak J Otolaryngol 1991; 7: 23-25.
14. Sirota P, Davidson B, Mosheva T, Benhatov R, Zohar J, Gross-Isseroff R. Increased olfactory sensitivity in treatment of schizophrenia. Psychiatry Res 1999; 86: 143-53.
15. Gilbert HS. Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 2002; 29: 22-27.
16. Kraus I, Vitezic D. Anosmia induced with alpha interferon in a patient with chronic hepatitis C. Int J Clin Pharmacol Ther 2000; 38: 360-61.
17. Varma RN. Risk for drug-induced malnutrition is unchecked in elderly patients in nursing homes. J Am Diet Assoc 1994; 94: 192-94.
18. Moorman JR. Digitalis toxicity at Duke Hospital, 1973 to 1984. South Med J 1985; 78: 561-64.
19. Adigun AQ, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure preliminary findings in cardiac cachexia. Eur J Heart Fail 2001; 3: 359-63.
20. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11: 131-45.
21. Vanina Y, Podolskaya A, Sedky K et al. Body-weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842-47.
22. Dursun SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? Can J Psychiatry 2001; 46: 287-88.
23. Stokes PE, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19: 1135-250.
24. Koda-Kimble, MA, Young, LY. Nausea and vomiting. In: Young, LY, Koda-Kimble, MA eds. Applied Therapeutics: The Clinical Use of Drugs. sixth edition. Vancouver, WA: Applied Therapeutics Inc., 1995: 1-11.
25. Ratnaike RN. Dysphagia: implications for older people. Rev Clin Gerontol 2003; 12: 283-94.
26. Prisant LM, Herman W. Calcium channel blocker induced gingival overgrowth. J Clin Hypertens 2002; 4: 310-311.
27. Menges M, Hohloch K, Pueschel W, Stallmach A. Lichen planus with oesophageal involvement. A case report and review of the literature. [Review] Digestion 2002; 65: 184-89.
28. Cahen P, Kirby AC, Porter SR, Olsen I. Regulation of LFA-3 (CD58) by dexamethasone and retinoic acids in vitro. Inflamm Res 2000: 49: 338-44.
29. Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994; 14: 561-71.
30. Katta R. Lichen planus. Am Fam Physician 2000; 1: 61: 3319-24, 3327-28.
31. Magro CM, Crowson AN. Lichenoid and granulomatous dermatitis. Int J Dermatol 2000; 39: 126-33.
32. Eisen D. The therapy of oral lichen planus. Crit Rev Oral Biol Med 1993; 4: 141-58.
33. Sugerman PB, Savage NW. Oral lichen planus: Causes, diagnosis and management. Aust Dent J 2002; 47: 290-97.
34. Navazesh M. Xerostomia in the aged [Review]. Dent Clin North Am 1989; 33: 75-80.
35. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology 1986; 5: 75-99.
36. Loesche WJ, Bromberg J, Terpenning MS, et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. Am Geriatr Soc 1995; 43: 401-07.
37. Molander L, Birkhed D. Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects. Psychopharmacology 1981; 75: 114-18.
38. Davies AN, Bradley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 2001; 22: 820-25.
39. Rowe JW, Andrew R, Tobin JD, Noris AH, Shock NW. Age-adjusted standards for creatinine clearance. Ann Intern Med 1976; 84: 567-69.
40. Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of neuroleptic malignant syndrome. [Review]. Gen Pharmacol 1990; 21: 367-86.
41. World Health Organization. The Management and Prevention of Diarrhoea. Programme for Control of Diarrhoeal Disease, third edition. Geneva: World Health Organization, 1993.
42. Powell DW. Approach to the patient with diarrhoea. In: Yamada T ed. Textbook of Gastroenterology. Philadelphia: Lippincott, 1991: 750.
43. Rybolt AH, Bennett RG, Laughon BE et al. Protein-losing enteropathy associated with Clostridium difficile infection. Lancet 1989; 1: 1353-55.
44. Gambert SR, Guansing AR. Protein-calorie malnutrition in the elderly. J Am Geriatr Soc 1980; 28: 272-75.
45. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective [Review]. Ann Intern Med 1973; 78: 271-76.
46. Ramaike RN. Non-immunological defence mechanisms. In: Ratnaike N ed. Small Bowel Disorders. London: Edward Arnold, 2000: 68-76.
47. Clough JD, Mims LH, Strober W. Deficient IgA antibody responses to arsanilic bovine serum albumin (BSA) in neonatally thymectomized rabbits. J Immunol 1971; 106: 1624-1629.
48. Good R. Introduction: The proceedings of the clinical symposium on the recognition and management of immunodeficiency disorders. Vox Sang 1986; 51: 1-13.
49. Makinodan T, Kay MM. Age influence on the immune system. Adv Immunol 1980; 29: 287-330.
50. Venarucci D, Vallese A, Catalini P, Venarucci V. Consideration on diminished immunologic defences in the elderly neoplastic subject. Panminerva Medica 1993; 35: 154-58.
51. Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993; 41: 940-46.
52. Papadopolous C, Kalantzis N, Rekoumis G, Kanaghinis T. A comparative trial of 400 mg cimetidine twice daily and 100 mg daily in the short-term treatment of duodenal ulceration. Curr Med Res Opin 1985; 9: 511-15.
53. Hamilton I, O'Connor HJ, Wood NC, Bradbury I, Axon AT. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrate bismuthate (TDB) tablets or cimetidine. Gut 1986; 27: 106-10.
54. Thorens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-59.
55. Gerson LB, Hatton BN, Ryono R et al. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 397-406.
56. Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci 1986; 31: 147S-162S.
57. Rolfe DR. Interactions among micro-organisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis 1984; 6: S73-79.
58. Sims RV, Hauser RJ, Adewale AO et al. Acute gastroenteritis in three community-based nursing homes. J Gerontol Series A, Biol Sci Med Sci 1996; 50: M252-M256.
59. Samuel SC, Hancock P, Leigh DA. An investigation into Clostridium perfringens enterotoxin-associated diarrhoea. J Hosp Infect 1991; 18: 219-30.
60. DuPont HL. Nosocomial salmonellosis and shigellosis (editorial: comment) Infect Control Hosp Epidemiol 1991; 12: 707-09.
61. Simon AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term care facility. Clin Infect Dis 1993; 17: 672-78.
62. Samore MH, Bettin KM, DeGirolami PC, Clabots CR, Gerding DN, Karchmer AW. Wide diversity of Clostridium difficile types at a tertiary referral hospital. J Infect Dis 1994; 170: 615-21.
63. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-54.
64. Bradbury AW, Barrett S. Surgical aspects of Clostridium difficile colitis. Br J Surg 1997; 84: 150-59.
65. Ravdin JI, Guerrant RL. Infectious diarrhoea in the elderly. Geriatrics 1983; 38: 95-97, 99-100.
66. Tobin MV, Fisken RA, Diggory RT, Morris AL, Gilmore IT. Orocaecal transit time in health and in thyroid disease. Gut 1989; 30: 26-29.
67. Rahman Q, Haboubi NY, Hudson PR, Lee GS, Shah IU. The effect of thyroxine on small intestinal motility in the elderly. Clin Endocrinol 1991; 35: 443-46.
68. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested micro-organisms in man: Studies in vivo and in vitro. Gut 1972; 13: 251-56.
69. Zemlan FP, Keys M, Richter RW et al. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996; 58: 1823-32.
70. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Arch Intern Med 1995; 155: 1766-72.
71. Morris DL, Youngs D, Muscroft TJ et al. Mutagenicity in gastric juice. Gut 1984; 25: 723-27.
72. Hunt RH. The protective role of gastric acid. Scand J Gastroenterol 1988; 23: 34-39.
73. Rivory LP. Irinotecan (CPT-11): a brief overview. Clin Exp Pharmacol Physiol 1996; 23: 1000-04.
74. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996; 32A: S18-S23.
75. Cain GD, Reiner EB, Patterson M. Effects of neomycin on disaccharidase activity of the small bowel. Arch Int Med 1968; 122: 311-14.
76. rd, Herrero BA, Mansbach CM. Morphologic alterations associated with neomycin-induced malabsorption. Am J Med Sci 1968; 255: 63-77.
77. Stemmermann GN, Hayashi T. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Hum Pathol 1971; 2: 321-32.
78. Horie T, Atakura Y, Fuwa T. Alleviation by garlic of antitumor drug-induced damage to the intestine. J Nutr 2001; 131: 1071S-4S.
79. Field M, Rao MC, Chang EB. Intestinal electrolyte transport and diarrheal disease (1). N Engl J Med 1989; 321: 800-06.
80. Field M, Rao MC, Chang EB. Intestinal electrolyte transport and diarrheal disease (2). N Engl J Med 1989; 321: 879-83.
81. Pentland B, Pennington CR. Acute diarrhoea in the elderly. Age Ageing 1980; 9: 90-92.
82. Andrews PA, Wilkinson PR. Diarrhoea as a side-effect of digoxin. BMJ 1990; 301 (6765): 1398.
83. Hardcastle J.Hardcastle PT, Kelleher DK et al. Effect on Auranofin on absorptive processes in the rat small bowel. J Rheumatol 1986; 13: 541-46.
84. Champion GD, Cairns DR, Bieri D et al. Dose response studies and long term evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988; 15: 28-34.
85. Ehrenfeld M, Levy M, Sharon P et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci 1982; 27: 723-27.
86. Verne GN, Eaker EY, David RH, Sninsky CA. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. Dig Dis Sci 1997; 42: 1959-63.
87. Scheurlen C, Allgayer H, Kruis W, Erdmann E, Sauerbruch T. Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? Clin Invest 1993; 71: 286-89.
88. Martenson JA. Jr, Hyland G, Moertel CG et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomised clinical trial. Int J Radiat Oncol Biol Phys 1996; 35: 299-303.
89. Martin AE, Montgomery PA. Acarbose: an alpha-glucosidase inhibitor. Am J Health Syst Pharm 1996; 53: 2277-90; quiz 2336-37.
90. Clausen MR, Bonnen B, Tvede M et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterol 1991; 101: 1497-504.
91. Robinson JD, Burtner DE. Severe diarrhea secondary to propranolol. Drug Intell Clin Pharm 1981; 15: 49-50.
92. O'Brien J.Thompson DG, Burnham WR et al. Beta-blocking drugs accelerate the passage of carbohydrate to the colon. Gut 1986; 27: 629.
93. Bytzer P, Stokholm M, Andersen I, Klitgaard NA, Schaffalitzky de Muckadell OB. Prevalence of surreptitious laxative abuse in patients with diarrhoea of uncertain origin: a cost benefit analysis of a screening procedure. Gut 1989; 30: 1379-84.
94. Duncan A, Morris AJ, Cameron A, Stewart MJ, Brydon WG, Russell RI. Laxative-induced diarrhoea - a neglected diagnosis. J Royal Soc Med 1992; 85: 203-05.
95. Roe DA. Drug-nutrient interactions in the elderly. Geriatrics 1977; 41: 57-59.
96. Suter PM, Russell RM. Vitamin requirements of the elderly. Am J Clin Nutr 1987; 45: 501-12.
97. Bailey AL, Maisey S, Southon S, Wright AJ, Finglas PM, Fulcher RA. Relationships between micronutrient intake and biochemical indicators of nutrient adequacy in a free-living elderly UK population. Br J Nutrit 1997; 77: 225-42.
98. Russell RM. New views on the RDAs for older adults. J Am Dietetic Assoc 1997; 97: 515-18.
99. Trovato A, Nuchlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician 1991; 44: 1651-58.
100. Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983; 24: 16-18.